GlassScriptPhysician profile
Vincent Campion
NPI 1578096137
$5,457.63
in general payments reported to CMS, 2019-2025
24 companies · $2,009 in 2025
The $2,009 reported for 2025 was more than what 89% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $627 · 2023: $1,272 · 2024: $1,550 · 2025: $2,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,076 · Education: $755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,076.00 |
| Education | $754.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,285.13 | 2022-2025 | |
| Opko Pharmaceuticals, LLC | $676.43 | 2022-2025 | Rayaldee |
| Astrazeneca Pharmaceuticals LP | $667.73 | 2022-2025 | Lokelma, Farxiga |
| Amgen INC. | $569.62 | 2022-2025 | Krystexxa, Tavneos |
| Mallinckrodt Hospital Products INC. | $542.42 | 2023-2025 | Acthar, Terlivaz |
| Calliditas Therapeutics US INC. | $270.65 | 2022-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $261.16 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.49 | 2023-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $164.99 | 2022-2025 | Jynarque, Voyxact |
| Horizon Therapeutics Plc | $127.05 | 2022-2023 | Krystexxa |
| Novo Nordisk INC | $109.80 | 2023-2025 | Ozempic |
| Novartis Pharmaceuticals Corporation | $97.32 | 2025 | |
| Ardelyx, INC. | $93.11 | 2025 | Ibsrela |
| Vifor Pharma, INC. | $78.47 | 2022-2023 | Veltassa |
| Akebia Therapeutics INC | $53.15 | 2025 | Vafseo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $47.12 | 2023-2024 | Benlysta, Jesduvroq |
| Cormedix INC. | $45.82 | 2024 | Defencath |
| Outset Medical INC | $31.66 | 2023 | |
| Chiesi USA, INC. | $29.74 | 2024 | Elfabrio |
| Ascendis Pharma Endocrinology INC | $26.19 | 2025 | Yorvipath |
| Lilly USA, LLC | $24.44 | 2025 | Jardiance |
| Nxstage Medical, INC. | $23.99 | 2025 | Liberty Select Cycler, Nxstage System One |
| Boston Scientific Corporation | $19.78 | 2023 | |
| Alexion Pharmaceuticals, INC. | $18.37 | 2025 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Campion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.